India’s pharmaceutical industry is poised for significant growth and could expand from its current size of around $60 billion to nearly $120 billion over the next five years, according to Union Commerce and Industry Minister Piyush Goyal. The projection reflects growing confidence in the sector’s ability to move beyond its traditional strengths and emerge as a global hub for innovation-driven healthcare solutions.
Addressing industry stakeholders at a pharmaceutical sector event in New Delhi, Goyal highlighted that India’s future growth will be driven not only by its well-established generic medicines industry but also by greater emphasis on research, innovation, intellectual property creation, and advanced manufacturing. He said the country is increasingly positioning itself as a destination for high-value pharmaceutical products and cutting-edge healthcare technologies.
India is already recognised globally as the “Pharmacy of the World” due to its extensive production of affordable medicines and vaccines. The country has the highest number of US FDA-approved pharmaceutical manufacturing facilities outside the United States and supplies a significant share of global vaccine requirements. These strengths have enabled India to become a trusted healthcare partner for countries across the world.
Goyal noted that the next phase of growth will require the industry to focus more strongly on innovation and the development of new therapies. While generic medicines will continue to remain an important pillar of the sector, investment in research and development is expected to create new opportunities in emerging areas such as biotechnology, specialty drugs, and advanced healthcare solutions.
The minister also invited global pharmaceutical companies to collaborate with India, highlighting the country’s large consumer base, skilled workforce, and rapidly expanding economy. He stressed that India offers an attractive environment for companies seeking to establish research, manufacturing, and innovation centres while serving both domestic and international markets.
Government initiatives aimed at strengthening the pharmaceutical and biotechnology ecosystem are expected to further support this growth trajectory. Programmes such as the proposed Biopharma Shakti mission and efforts to improve ease of doing business are intended to encourage investment, enhance research capabilities, and strengthen India’s position in global supply chains.
Industry experts believe that rising global demand for affordable healthcare products, expanding export opportunities, and increasing domestic consumption will continue to drive growth in the sector. India’s pharmaceutical exports have already shown steady progress, reinforcing the country’s role as a key supplier of medicines to international markets.
The projected doubling of the industry’s size underscores the growing importance of pharmaceuticals in India’s economic and healthcare landscape. With a combination of manufacturing excellence, innovation-led growth, and stronger global partnerships, the sector is expected to play an even larger role in shaping the future of healthcare worldwide while contributing significantly to India’s economic development.
